Glimepirid Al (Glimepiride)

Glimepirid Al is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient.

• As monotherapy in adults with type 2 diabetes inadequately controlled by lifestyle measures.
• In combination with metformin when additional glucose lowering is required.
• As part of a fixed‑dose combination regimen with other oral antidiabetic agents.
• To improve glycemic control in patients who have a preserved pancreatic beta‑cell function.
• For use in patients who require a once‑daily oral sulfonylurea.

Glimepirid Al may cause a range of adverse effects, most of which are dose‑related and reversible after discontinuation. These events are reported in clinical studies and post‑marketing surveillance.

Common

• Mild hypoglycemia, especially when meals are skipped or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient visual disturbances.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as rash, pruritus, or angio‑edema.
• Hematologic abnormalities including leukopenia or thrombocytopenia.
• Hepatic dysfunction presenting as elevated transaminases.
• Severe hypoglycemia leading to loss of consciousness.

Before prescribing Glimepirid Al, clinicians should evaluate patient history and monitor specific conditions to minimize risk.

• Assess renal and hepatic function; dose adjustment may be required in impairment.
• Verify that the patient has adequate pancreatic beta‑cell reserve.
• Caution in elderly patients due to increased susceptibility to hypoglycemia.
• Avoid use in patients with known sulfonylurea hypersensitivity.
• Counsel patients on recognizing and managing hypoglycemic episodes.
• Review concomitant use of alcohol, which can potentiate hypoglycemia.

Glimepirid Al can interact with several medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can raise glimepiride plasma levels.
• Discontinuation of beta‑blockers without medical guidance, as they may mask hypoglycemia symptoms.
• High‑dose corticosteroids, which may counteract the drug’s efficacy.

Use with caution

• Loop or thiazide diuretics, which can affect blood glucose control.
• Antifungal agents like itraconazole that moderately inhibit CYP2C9.
• NSAIDs and aspirin, which may enhance the hypoglycemic effect.
• Thyroid hormones, which may alter glucose metabolism.